Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.

@article{Hultsch2005ImmunomodulationAS,
  title={Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.},
  author={Thomas Hultsch and Alexander Kapp and Jonathan M Spergel},
  journal={Dermatology},
  year={2005},
  volume={211 2},
  pages={174-87}
}
Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin condition that primarily affects children. Topical corticosteroids have been the mainstay of treatment since the late 1950s. While providing excellent short-term efficacy, topical corticosteroid usage is limited by potential adverse effects, including impairment of the function and viability of Langerhans cells/dendritic cells. The recently introduced topical calcineurin inhibitors pimecrolimus cream 1% (Elidel) and… CONTINUE READING